We are live on ! Find out more
AZN icon

AstraZeneca

390 hedge funds and large institutions have $7.54B invested in AstraZeneca in 2015 Q4 according to their latest regulatory filings, with 55 funds opening new positions, 137 increasing their positions, 108 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 55 | Existing positions closed: 33

33% more funds holding in top 10

Funds holding in top 10: 34 (+1)

27% more repeat investments, than reductions

Existing positions increased: 137 | Existing positions reduced: 108

15% more capital invested

Capital invested by funds: $6.54B → $7.54B (+$998M)

15% more call options, than puts

Call options by funds: $70.5M | Put options by funds: $61.5M

5% more funds holding

Funds holding: 371390 (+19)

0.65% more ownership

Funds ownership: 8.13%8.79% (+0.65%)

Holders
390
Holders Change
+19
Holders Change %
+5.12%
% of All Funds
10.2%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.1%
New
55
Increased
137
Reduced
108
Closed
33
Calls
$70.5M
Puts
$61.5M
Net Calls
+$8.98M
Net Calls Change
-$17M

AZN Hedge Fund Activity: Q4 2015 in Review

390 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q4 2015, worth a combined $7.54B — up 15% from $6.54B a quarter earlier.

Buyers outnumbered sellers: 55 funds opened new AZN positions and 33 closed out — a net gain of 22 holders — while 137 added to existing stakes and 108 trimmed.

The largest buyer was Dodge & Cox, opening a new position worth an estimated $386M. The largest seller was Arrowstreet Capital, cutting an estimated $43.9M.

  • 390 institutional investors held AstraZeneca (AZN) as of Q4 2015, up from 371 in Q3 2015.
  • Funds reported $7.54B of AstraZeneca stock for Q4 2015, up 15% quarter-over-quarter.
  • 55 funds opened new AstraZeneca positions in Q4 2015 and 33 closed out, a net change of +22 holders.
  • The largest AstraZeneca buyer in Q4 2015 was Dodge & Cox, an estimated $386M added.
  • The largest AstraZeneca seller in Q4 2015 was Arrowstreet Capital, an estimated $43.9M sold.

Based on aggregated 13F filings for Q4 2015.